OpenProtein.AI, a US company that bills itself as a leader in AI-powered protein engineering software, has announced an expanded partnership with privately held German pharmaceutical company Boehringer Ingelheim to co-develop specialized antibody discovery and optimization workflows.
This article is accessible to registered users. Register for free to read more. Your free trial gives you one week of access to exclusive features, interviews, recaps, and commentary from some of the sharpest minds in pharma and biotech. If you are already a registered user, please log in. If your trial is over, you can subscribe here.
Log into your account
TRY BEFORE YOU BUY
free
7-day trial access
Try a free trial
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analysis and commentary from our global network of life science reporters.
- Receive The Pharma Letter’s daily news bulletins free forever.
become a subscriber
£820
or £77 per month
Subscribe now
- Free access to industry-leading news, commentary and analysis in Pharma & Biotechnology.
- Latest information from clinical trials, conferences, M&A, licensing, financing, regulation, patents and legislation, executive appointments, commercial strategy, and financial results.
- A daily roundup of important events in pharma and biotechnology.
- We hold monthly in-depth briefings on board appointments and M&A news.
- Choose from cost-effective annual packages or flexible monthly subscriptions
Pharma Letter is a highly useful and valuable life sciences service that brings together daily updates on high-performing people and products. This is some important information to keep me informed
Chairman of Sanofi-Aventis UK
